Publications by authors named "Pascal Chanu"

Claim this Profile
P
Pharmacokinetic and pharmacodynamic modelling of continuous erythropoiesis receptor activator in children: A comprehensive analysis and real-world data validation.
Samer Mouksassi, Franz Schaefer, Bradley A Warady, Claus P Schmitt, Sylvie Meyer Reigner, Pascal Chanu

Br J Clin Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Modeling and External Model Evaluation Through Clinical Data Sharing Platform for HR+/HER2- Breast Cancer.
Kenta Yoshida, René Bruno, Pascal Chanu

CPT Pharmacometrics Syst Pharmacol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Real-World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug-Drug Interaction Risk in Target Patient Populations.
Alice S Tang, Logan Brooks, Denise M Boudreau, Pascal Chanu, Amita Joshi

Clin Pharmacol Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Exposure-Response of Subcutaneous Atezolizumab in Patients With Non-Small Cell Lung Cancer.
Phyllis Chan, Stephanie N Liu, Nathalie Gosselin, Zacharie Sauve, Mathilde Marchand, Pascal Chanu

CPT Pharmacometrics Syst Pharmacol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma.
Chi-Chung Li, Brendan Bender, Justin Wilkins, Feifei Li, David C Turner, Pascal Chanu

Clin Pharmacol Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding the use of real-world data through the development of user-friendly tools to support drug development: Example of an organ impairment dashboard.
Bianca Vora, Erick Velasquez, Rong Zhang, Krystian Igras, Spencer L James, Pascal Chanu

Pharmacol Res Perspect· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches.
Mathilde Marchand, Antonio Gonçalves, François Mercier, Pascal Chanu, Jin Y Jin

CPT Pharmacometrics Syst Pharmacol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.
Brendan Bender, Chi-Chung Li, Mathilde Marchand, David C Turner, Feifei Li, Pascal Chanu

Clin Transl Sci· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models.
René Bruno, Pascal Chanu, Matts Kågedal, Francois Mercier, Kenta Yoshida

Br J Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective.
Rui Zhu, Bianca Vora, Sujatha Menon, Islam Younis, Gaurav Dwivedi, Pascal Chanu

Clin Pharmacol Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Pascal Chanu

Clin Cancer Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB.
Samira Jamalian, Michael Dolton, Pascal Chanu, Vidya Ramakrishnan, Yesenia Franco

CPT Pharmacometrics Syst Pharmacol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Pascal Chanu

Clin Cancer Res· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study.
Naoki Kotani, Justin J Wilkins, Janet R Wade, Steve Dang, Dhruvitkumar S Sutaria, Pascal Chanu

Cancer Chemother Pharmacol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy.
Cristina Julian, Robson J M Machado, Sandhya Girish, Pascal Chanu, Dominik Heinzmann

Cancer Rep (Hoboken)· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors.
Weize Huang, Felix Stader, Phyllis Chan, Colby S Shemesh, Yuan Chen, Pascal Chanu

Front Pharmacol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients.
Kenta Yoshida, Justin Wilkins, Julia Winkler, Janet R Wade, Naoki Kotani, Pascal Chanu

J Clin Pharmacol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Enriqueta Felip, Mauricio Burotto, Zanete Zvirbule, Luis A Herraez-Baranda, Pascal Chanu

Clin Pharmacol Drug Dev· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation.
Pascal Chanu, Luna Musib, Xin Wang, Sravanthi Cheeti, Sandhya Girish

J Invest Dermatol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
Tong Lu, Leonid Gibiansky, Xiaobin Li, Chunze Li, Rong Shi, Pascal Chanu

Leuk Lymphoma· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
Dan Lu, Tong Lu, Rong Shi, Leonid Gibiansky, Priya Agarwal, Pascal Chanu

Pharm Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-based approach for methoxy polyethylene glycol-epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease.
Pascal Chanu, Franz Schaefer, Bradley A Warady, Claus Peter Schmitt, Bruno Reigner

Br J Clin Pharmacol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.
Dan Lu, Tong Lu, Leonid Gibiansky, Xiaobin Li, Chunze Li, Pascal Chanu

CPT Pharmacometrics Syst Pharmacol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.
Colby S Shemesh, Pascal Chanu, Kris Jamsen, Russ Wada, Gianluca Rossato

J Immunother Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A modeling and simulation-based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension.
Pascal Chanu, Xiang Gao, Rene Bruno, Laurent Claret, Lutz Harnisch

J Pharmacokinet Pharmacodyn· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis